These 9 biotech stocks have doubled this year and are set to double again, analysts say

Nine health-care stocks have more than doubled in price this year, but still have more than 100% upside potential, according to analysts.

Pro screened more than 85,000 firms worldwide for stocks that have risen by 100% so far in 2024. They are all covered by at least five or more analysts, and a have a median price target pointing to more than 100% upside potential over the next 12 months. The Nasdaq-listed stocks are Jasper Therapeutics , Corbus Pharmaceuticals , Rezolute , Trevi Therapeutics , Delcath Systems , Benitec Biopharma , Arcutis Biotherapeutics , Praxis Precision Medicines and Humacyte .

대한민국 최근 뉴스, 대한민국 헤드 라인